Inventor · disambiguated record
Marcela Maus
Also filed as: MAUS MARCELA · MAUS MARCELA V
24 granted patents·25 pending applications·530 citations·filing 2003–2025
96Inventor score
Top patents by PatentIndex Score
49 records- 0196US9394368B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorBROGDON JENNIFER·Filed 2014·Granted Jul 19, 2016·112 cites·38 claims
- 0296US8637307B2Activation and expansion of T-cells using an engineered multivalent signaling platform as a research toolJUNE CARL H·Filed 2010·Granted Jan 28, 2014·143 cites·4 claims
- 0395US10927184B2Treatment of cancer using humanized anti-CD19 chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 23, 2021·10 cites·26 claims
- 0495US10357514B2Treatment of cancer using anti-CD19 Chimeric Antigen ReceptorUNIV PENNSYLVANIA·Filed 2015·Granted Jul 23, 2019·18 cites·45 claims
- 0595US10221245B2Treatment of cancer using humanized anti-CD19 chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted Mar 5, 2019·36 cites·67 claims
- 0695US7745140B2Activation and expansion of T-cells using an engineered multivalent signaling platform as a research toolUNIV PENNSYLVANIA·Filed 2003·Granted Jun 29, 2010·85 cites·26 claims
- 0793US7638326B2Activation and expansion of T-cells using an engineered multivalent signaling platformUNIV PENNSYLVANIA·Filed 2003·Granted Dec 29, 2009·68 cites·15 claims
- 0890US7638325B2Activation and expansion of T-cells using an engineered multivalent signaling platformUNIV PENNSYLVANIA·Filed 2003·Granted Dec 29, 2009·35 cites·12 claims
- 0989US10308717B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Jun 4, 2019·4 cites·9 claims
- 1088US11865167B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorNOVARTIS AG·Filed 2019·Granted Jan 9, 2024·2 cites·39 claims
- 1186US11578115B2Chimeric antigen receptors based on alternative signal 1 domainsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Feb 14, 2023·3 cites·28 claims
- 1282US7670781B2Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signalUNIV PENNSYLVANIA·Filed 2003·Granted Mar 2, 2010·11 cites·15 claims
- 1377US11352434B2Chimeric antigen receptors targeting CD37MASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Jun 7, 2022·1 cites·17 claims
- 1477US9453199B2Activation and expansion of T-cells using an engineered multivalent signaling platform as a research toolUNIV PENNSYLVANIA·Filed 2013·Granted Sep 27, 2016·1 cites·2 claims
- 1575US12049482B2Molecular switch-mediated control of engineered cellsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Jul 30, 2024·1 cites·16 claims
- 1673US2024075070A1Chimeric antigen receptor t cells targeting the tumor microenvironmentMASSACHUSETTS GEN HOSPITAL·Filed 2023·Application pending·0 cites
- 1770US2023322923A1Methods and compositions relating to ex vivo culture and modulation of t cellsMASSACHUSETTS GEN HOSPITAL·Filed 2023·Application pending·0 cites
- 1869US11559589B2Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapyCHILDRENS HOSPITAL PHILADELPHIA·Filed 2018·Granted Jan 24, 2023·0 cites·6 claims
- 1969US9075044B2Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapyHIGH KATHERINE A·Filed 2007·Granted Jul 7, 2015·0 cites·5 claims
- 2069US2025074957A1Molecular switch-mediated control of engineered cellsMASSACHUSETTS GEN HOSPITAL·Filed 2024·Application pending·0 cites
- 2167US2025249037A1Cd70 binding car-t cells comprising cd33 binding t-cell engaging antibody moleculesMASSACHUSETTS GEN HOSPITAL·Filed 2023·Application pending·0 cites
- 2267US2023250150A1Chimeric antigen receptors based on alternative signal 1 domainsMASSACHUSETTS GEN HOSPITAL·Filed 2022·Application pending·0 cites
- 2367US2025325585A1Compositions and methods for reducing cell therapy immunogenicityMASSACHUSETTS GEN HOSPITAL·Filed 2023·Application pending·0 cites
- 2465US12378297B2Chimeric antigen receptor T cells targeting the tumor microenvironmentMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Aug 5, 2025·0 cites·24 claims
- 2564US12459975B2Modified T cells and methods of their useMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Nov 4, 2025·0 cites·17 claims
- 2664US11613574B2Methods and compositions relating to ex vivo culture and modulation of T cellsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Mar 28, 2023·0 cites·17 claims
- 2763US2019177692A1Activation and Expansion of T-Cells Using an Engineered Multivalent Signaling Platform as a Research ToolUNIV PENNSYLVANIA·Filed 2018·Application pending·0 cites
- 2863US2023167190A1Chimeric antigen receptors targeting cd37MASSACHUSETTS GEN HOSPITAL·Filed 2022·Application pending·0 cites
- 2962US2019388471A1Treatment of cancer using anti-cd19 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3061US2016348072A1Activation and Expansion of T-Cells Using an Engineered Multivalent Signaling Platform as a Research ToolUNIV PENNSYLVANIA·Filed 2016·Application pending·0 cites
- 3160US2025000978A1Anti-mesothelin car t cells secreting teams and methods of use thereofMASSACHUSETTS GEN HOSPITAL·Filed 2022·Application pending·0 cites
- 3259US12161668B2T cells expressing a chimeric antigen receptorMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Dec 10, 2024·0 cites·18 claims
- 3359US2025186496A1Methods and compositions for controlling t cell activationMASSACHUSETTS GEN HOSPITAL·Filed 2023·Application pending·0 cites
- 3458US11332513B2Chimeric antigen receptors having GITR intracellular domain as co-stimulatory domainPROMAB BIOTECHNOLOGIES INC·Filed 2019·Granted May 17, 2022·0 cites·7 claims
- 3556US2015320886A1Compositions and methods for detection and modulation of t cell mediated immune responses against viral vectors utilized for gene therapyPHILADELPHIA CHILDREN HOSPITAL·Filed 2015·Application pending·0 cites
- 3653US2022411478A1Cd70 targeted chimeric antigen receptor (car) t cells and uses thereofMASSACHUSETTS GEN HOSPITAL·Filed 2020·Application pending·0 cites
- 3753US2023036569A1Engineered immune cells with reduced toxicity and uses thereofMASSACHUSETTS GEN HOSPITAL·Filed 2020·Application pending·0 cites
- 3852US2021268027A1Chimeric antigen receptors targeting cd37 and cd19MASSACHUSETTS GEN HOSPITAL·Filed 2019·Application pending·0 cites
- 3952US2021322473A1Modified t cells and methods of their useMASSACHUSETTS GEN HOSPITAL·Filed 2019·Application pending·0 cites
- 4051US12473343B2Targeted t cells with cytotoxicity toward immunosuppressive cellsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Nov 18, 2025·0 cites·10 claims
- 4151US12409249B2Compositions and methods for immune toleranceMASSACHUSETTS INST TECHNOLOGY·Filed 2019·Granted Sep 9, 2025·0 cites·21 claims
- 4250US2021054086A1Immune cells expressing a chimeric antigen receptorMASSACHUSETTS GEN HOSPITAL·Filed 2019·Application pending·0 cites
- 4348US2020207852A1T cells expressing a chimeric antigen receptorMASSACHUSETTS GEN HOSPITAL·Filed 2018·Application pending·0 cites
- 4448US2022170097A1Car t cell transcriptional atlasBROAD INST INC·Filed 2019·Application pending·0 cites
- 4548US2021277120A1Compositions and methods for treatment of t cell malignanciesMASSACHUSETTS GEN HOSPITAL·Filed 2019·Application pending·0 cites
- 4648US2025241955A1Engineered bifunctional receptors and uses thereofMASSACHUSETTS GEN HOSPITAL·Filed 2025·Application pending·0 cites
- 4746US2021038646A1Chimeric antigen receptors targeting the tumor microenvironmentMASSACHUSETTS GEN HOSPITAL·Filed 2019·Application pending·0 cites
- 4840US2020330515A1Methods and compositions relating to engineered regulatory t cellsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Application pending·0 cites
- 4933US2018140602A1Combination of chimeric antigen receptor therapy and amino pyrimidine derivativesANGST DANIELA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marcela Maus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →